Objectives: Gastrointestinal (GI) bleeding is a major comorbidity in patients with left ventricular assist devices (LVADs). The study aim was to estimate the rate of hospital readmissions for GI bleeding in patients with LVADs using a nationally representative database. Additionally, we evaluated the etiologies, costs, endoscopy utilization, mortality, and predictors of GI bleeding readmissions in these patients.
L eft ventricular assist devices (LVADs) are cardiac support devices that traditionally were used as a bridge to heart transplant in patients with end-stage congestive heart failure (CHF). With ongoing organ shortage and improved outcomes, however, these devices also are used as a destination therapy in patients Key Points
• After left ventricular assist device (LVAD) implantation, patients with congestive heart failure have an approximately fivefold increased risk of readmission with gastrointestinal (GI) bleeding within 60 days posthospital discharge.
• Gastroduodenal and small intestinal arteriovenous malformations are the most common culprit lesions.
• Older age and bleeding during index admission for LVAD implantation are independent predictors of rebleeding.
• In LVAD patients without GI bleeding during LVAD implantation, chronic anemia is associated with an increased risk of de novo GI bleeding readmission.
• GI bleeding in patients with LVAD is associated with a higher rate than that in control patients with congestive heart failure of endoscopy utilization and blood transfusion, longer length of stay, and higher total costs. who are not candidates for transplant. 1 The ratio of LVAD implants to transplants is increasing steadily. 2 Several studies have found that LVADs improve quality of life without major adverse effects. [3] [4] [5] More than 2000 continuous flow LVADs are implanted annually in the United States. 6 With the increasing use of LVAD devices, readmissions resulting from various LVAD-related complications also have increased. 6 Gastrointestinal (GI) bleeding is an important complication after LVAD implantation. [7] [8] [9] The reported incidence of GI bleeding with heart assist devices ranges from 18% to 40% within 6 months after implantation. 10, 11 The etiology of increased bleeding risk associated with LVAD is unclear but likely multifactorial. These patients are placed on anticoagulation and antiplatelet therapy, which increases bleeding risk. 12 LVADs may lead to pathologic degradation of von Willebrand factor (vWF), which regulates multiple vascular pathways, leading to increased risk of bleeding from preexisting GI arteriovenous malformations (AVMs). Some have suggested that reduced pulse pressure associated with LVADs leads to intestinal hypoperfusion, local hypoxia, vascular dilation, and AVM formation. 13 Data related to the rates and etiologies of GI bleeding in patients with LVADs remain scarce and limited to single-center studies. There are no national estimates of GI bleeding readmissions following LVAD implantation, compared with control CHF patients without LVADs. Furthermore, there are no population studies to evaluate the cost, endoscopy utilization, and mortality in GI bleeding readmissions. Identifying the predictors of GI bleeding readmission helps to implement preventive strategies aimed at reducing bleeding in patients at high risk.
In this study we used a large, nationally representative database to provide national estimates of the rates of all-cause and GI bleeding readmissions in patients with LVADs compared with CHF controls without LVADs. In addition, we evaluate bleeding characteristics, endoscopy utilization, costs, mortality, and predictors of GI bleeding readmission in patients with LVADs.
Methods
The data source for this study was the National Readmissions Database (NRD), 2010-2014. The NRD is produced by the Healthcare Cost and Utilization Project (HCUP), which is sponsored by the Agency for Healthcare Research and Quality (AHRQ). The database tracks patient discharges and admissions across all of the hospitals within a state. The NRD represents 49.3% of all hospitalizations within the United States.
14 Each hospitalization contains >100 patient-and hospital-related variables, including up to 25 diagnosis (dx) codes (dx1-dx25), 20 procedure codes (pr1-pr20), and 29 predefined comorbidity variables. In addition, the NRD contains a Clinical Classifications Software (CCS) classification related to each diagnosis (CCS1-CCS25). These classifications are based on the CCS for the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) developed by the AHRQ to organize ICD-9-CM codes into specific categories. This study was deemed exempt from review by the Emory University institutional review board because the database does not contain any identifiable information that can be linked to any specific subject.
Study Population and Study Groups
We selected our patient population based on the ICD-9-CM codes listed in the admission diagnosis and procedural codes (Supplemental Digital Content Table 1 , http://links.lww.com/ SMJ/A123). We followed the recommendations of the HCUP in identifying index admissions and readmissions.
14, 15 We defined cases as adult patients (18 years old and older) with any diagnosis that had a clinical classification of "108-Congestive Heart Failure." We excluded patients who received a heart transplant during the admission or were assigned a code that indicated status postheart transplant. We also excluded patients who died during the hospitalization and those who were discharged in the months of November and December of each year (to have a full 60-day period to track readmissions postdischarge). LVAD cases had procedure code 3766 (insertion of implantable heart assist device). Potential control cases had neither procedure code 3766 nor code V4321 (status postheart assist device). The final control population was selected randomly from the control pool by using procedure "surveyselect" in SAS version 9.4 (SAS Institute, Cary, NC), stratifying by age category and sex. Three controls were selected randomly for each LVAD case. Patients were tracked using "NRD_visitlink" and "NRD_DaysToEvent" to identify all of the readmissions within a 60-day period following discharge from index hospitalization. To identify GI bleeding cases, we used specific ICD-9-CM codes that indicate bleeding throughout the GI tract. To identify bleeding etiology, specific bleeding codes (eg, gastric ulcer with bleeding) or nonspecific bleeding codes (eg, melena) combined with another code for etiology (eg, gastric ulcer) were used. We classified sources of bleeding as upper (esophageal and/or gastroduodenal), lower (colonic), and small intestinal bleeding.
Demographic and Hospital Variables
Patient demographic variables included age, sex, and median household income for each patient's ZIP code. Admission variables included primary payer information, weekend versus weekday admission, length of stay (LOS), and discharge disposition. Hospital characteristics included hospital control or ownership status, bed size, and teaching status. Comorbidity was measured by the Elixhauser readmission index, which is a validated measure of comorbidity derived from 29 predefined HCUP comorbidity variables and developed by the AHRQ using HCUP state inpatient sample data. It is designed specifically to assess the risk of readmissions and control for significant comorbidities in administrative data. 16 Comorbidities included in the score are listed in Supplemental Digital Content Table 2 (http:// links.lww.com/SMJ/A123). For cost estimations, we first converted hospital charges to cost estimates using the charge-to-cost ratios provided by the HCUP. Costs were inflated to 2017 US dollars using the Consumer Price Index for inpatient hospital services provided by the US Bureau of Labor Statistics.
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Outcomes
Our primary outcomes were the cumulative rates of allcause and GI bleeding readmissions at 60 days posthospital discharge from index admission. Our secondary outcomes were etiologies of GI bleeding, costs, endoscopy utilization, mortality, and predictors of increased 60-day GI bleeding readmissions.
Statistical Analysis
Categorical variables were described as number (percentage) and continuous variables were reported as the means ± standard deviations. Baseline characteristics of the control and LVAD groups were compared using the χ 2 test for categorical variables and the Student t test for continuous variables. Cox proportional hazards regression was used to compare the risk of 60-day readmissions between the LVAD and the control groups. The primary exposure variable was treatment with LVAD. Covariates that were considered for inclusion in the model were female sex, age, primary payer type, LOS, weekend admission, disposition, hospital control, bed size, and Elixhauser readmission index. Covariates with a P < 0.2 on the univariate analysis were entered into the model and retained if P < 0.05. To investigate the predictors of 60-day GI bleeding readmission in the LVAD group, we used Cox proportional hazards regression, with the primary outcome as GI bleeding readmission. We performed additional stratification per bleeding status during index admission. Covariates included GI bleeding during index admission, all of the aforementioned covariates, and all of the comorbidity variables listed in Supplementary Table 2, with the exception of CHF. The results of the Cox regression were expressed using the adjusted hazard ratio (aHR) and 95% confidence interval (CI). A two-tailed P value of 0.05 was used as the threshold for statistical significance.
Results
During the study period 2010-2014, 3293 admissions with CHF and LVAD implantation met the inclusion criteria, and 9879 ageand sex-matched controls were randomly selected from the pool of eligible controls (Fig. 1) . Baseline characteristics are shown in Table 1 . The LVAD group had a longer mean hospital stay (34 vs 6.1 days, P < 0.0001), whereas the Elixhauser readmission index was higher in the control group (26.8 vs 22.9, P < 0.0001). Patients with LVAD had a significantly higher rate of GI bleeding during index admission (6.5% vs 3.5%, P < 0.0001). Upper GI source of bleeding was the most common source of bleeding (63%). Gastroduodenal AVM and peptic ulcer disease were the most common etiologies for bleeding.
Readmission outcomes are summarized in Table 2 . Patients with LVAD had a significantly higher rate of 60-day all-cause readmission (43.3% vs 35.7%, aHR 1.23, 95% CI 1.24-1.34, P < 0.0001) and readmissions with GI bleeding (8.7% vs 2.3%, aHR 4.45, 95% CI 3.71-5.33, P < 0.0001) compared with the control group (Fig. 2) . The hazards of upper, small intestinal, and lower GI bleeding were higher in the LVAD group compared with controls. Small intestinal bleeding from AVM had the highest relative risk increase compared with the control group (1.2% vs. 0.1%, aHR 18.91, 95% CI 7.90-45.26, P < 0.0001). Table 3 shows the characteristics of GI bleeding readmissions in both groups. Patients in the LVAD group were more likely to experience bleeding from gastroduodenal AVMs (16.7%) and small intestinal AVMs (13.5%) as compared with the control group (<5%). The frequency of bleeding from peptic ulcer disease was similar in both groups (7%). There was no significant difference in the etiology of lower GI bleeding. Patients in the LVAD group were more likely to require endoscopy during their GI bleeding readmission (72.1% vs 33.5%, P < 0.0001) and more likely to require packed red blood cell transfusion (62.0% vs 36.6%, P < 0.0001) and serum fresh frozen plasma transfusion (13.2% vs 6.6%, P = 0.01) compared with controls. Small bowel enteroscopy (SBE) was the most common procedure in patients with LVADs (43.6% vs 11.5%, P < 0.0001). The average total cost of GI bleeding readmission was higher in patients with LVADs ($40,936 vs $35,313, P < 0.0001). The average LOS also was higher in the LVAD group (12 vs 10.9 days), whereas the overall mortality was similar in both groups (0.3% vs 0.2%, P = 0.14). Table 4 shows the all-cause readmission rates and admission diagnoses among the LVAD and control groups, based on the clinical classification of the first discharge diagnosis of the first readmission. The most common readmission diagnoses in the LVAD group were implant-related complications (14.9%), CHF (13.0%), and GI bleeding (7.7%). In the control group, the most common were CHF (19.9%), sepsis (5.8%), and chronic obstructive pulmonary disease (4.4%). The average total cost during readmission was higher in the LVAD group ($39,338 vs $19,189, P < 0.0001) and the average LOS was longer (9.8 vs 6.5 days, P < 0.0001) compared with controls. Both groups had similar mortality during all-cause readmission (1.3% vs 1.4%, P = 0.86). Table 5 lists predictors of 60-day readmission with GI bleeding in the LVAD group. On multivariable analysis, GI bleeding during index admission (HR 2.68, 95% CI 1.95-3.70) and age (HR 1.04, 95% CI 1.03-1.05) were independent predictors of 60-day readmission with GI bleeding. In patients with LVADs with bleeding during index hospitalization, age, obesity, and alcohol abuse were independent predictors of rebleeding. In LVAD patients without bleeding during index admission, age and deficiency anemias were independent predictors of readmission with de novo GI bleeding.
Discussion
In this study we used a nationally representative dataset with specific readmission identifiers to compare readmissions in patients with LVAD implantation with age-and sex-matched controls with CHF. Patients with LVADs have a 4.5-fold increase in the rate of readmission with GI bleeding within 60 days postdischarge from index admission with LVAD implantation compared with controls (adjusted odds ratio 4.45, 95% CI 3.71-5.33, P < 0.0001). They also had a higher risk of GI bleeding during index admission compared with controls (6.5% vs 3.5%, P < 0.0001). One previous study of the national inpatient sample found bleeding rates of 8% during hospitalization for LVAD implantation 18 ; however, this study reported the lower GI tract as the most common source of bleeding, in contrast to our study in which 63.1% of GI bleeding episodes were classified as upper GI bleeding. These differences are likely related to the coding scheme of upper and lower GI bleeding. Most important, we chose to classify ICD-9 code 578.1 (blood in stool/melena) as indicative of upper GI bleeding source, rather than as a nonspecific lower GI bleeding source. In our study GI AVMs accounted for 23.1% of GI bleeding during index admission. It is hypothesized that LVAD-associated GI bleeding is related to lower levels of high-molecular-weight vWF multimers and the formation of small bowel AVMs. 19 It is unclear whether these pathophysiological changes are so rapid as to explain GI bleeding in the acute setting after device implant. As we expected, our analysis showed that patients with LVADs had a higher overall cost of index admission, which is mainly related to the cost of LVAD implantation and prolonged LOS.
Upper GI source of bleeding was the most common presentation of bleeding in patients with LVADs (42.5%). This is in contrast to a study done on a national inpatient database, in which a lower GI source of bleeding was more commonly encountered in patients with LVADs (32%) and an upper GI source of bleeding was more commonly encountered in non-LVAD patients (52%). 20 We found that GI (gastroduodenal and small intestinal) AVMs were responsible for 28.6% of bleeding in the LVAD group, compared with <5% in controls (P < 0.0001). This finding supports the hypothesis that LVADs induce alterations in intestinal vascularity and lead to acquired defects in the vWF pathway, resulting in increased AVM formation. 19 We found that LVAD patients with GI bleeding require more aggressive management compared with control CHF patients with GI bleeding. Patients with LVADs were more likely to require endoscopy (72.1% vs 41.1%) and packed red blood cell transfusion (62.0% vs 36.6%) as compared with controls. Furthermore, hospital stay during readmission with GI bleeding was higher in the LVAD group (12 vs 0.9 days), and the total cost of readmission was higher compared with controls. Several factors may contribute to increased costs and LOS in patients with LVADs. These patients may require closer monitoring in the intensive care unit. Anticoagulation may preclude immediate endoscopic intervention in relatively stable patients, thus increasing the LOS. 21 It is recommended that endoscopic intervention is performed in the presence of a cardiac-trained anesthesiologist who is experienced in the care of patients with LVADs. 21 In our study SBE was the most commonly performed procedure in patients with LVADs (43.6%), and its use was more common than in controls (11.5%). As shown in previous studies, esophagogastroduodenoscopy is unrevealing in about two-thirds of patients, who subsequently require SBE, device (balloon)-assisted endoscopy, or both, increasing the utilization of endoscopic procedures. 22, 23 Based on the high frequency of small intestinal AVMs in these patients, SBE should be favored over esophagogastroduodenoscopy as the initial endoscopic evaluation of the upper GI tract.
Previous studies showed that GI bleeding during index hospitalization for LVAD placement does not increase mortality. 20 Our study demonstrates that also is true during readmission for GI bleeding, in which mortality was low in both the LVAD and control groups (0.2% and 0.3%).
In patients with LVADs, GI bleeding was the third most common cause of readmission, after LVAD-related complications and CHF. Previous single-center studies identified GI bleed as the most common cause of LVAD-related readmissions. 24, 25 Older age and GI bleeding during index admission for LVAD implantation were identified as independent predictors for 60-day readmission with GI bleeding. We found that in patients with LVADs who develop bleeding during index hospitalization, alcohol and obesity are independent predictors of rebleeding. There is no previously described association of obesity or alcohol as risk factors for recurrent GI bleeding in these patients. In LVAD patients without bleeding during index admission, increasing age and chronic anemia were associated with rebleeding during admission. Aggressive risk factor modification in these patients such as the use of proton pump inhibitors, evaluation and treatment of Helicobacter pylori, targeting a lower therapeutic anticoagulation level, and judicious use of antiplatelet medication where possible may help to reduce the risk of readmission with GI bleeding. Patients with chronic uninvestigated anemias should have a full workup and close follow-up.
Our study has several strengths. It is the first populationbased study to assess readmissions in patients with LVADs postdischarge from index hospitalization, and it is the largest study on this topic. We compared the incidence and characteristics of GI bleeding during index admission for LVAD implantation and readmissions, compared with CHF controls without LVAD. Our findings provide detailed estimates of the absolute and relative risks of bleeding after LVAD implantation, which can be used to inform providers and patients. Preventive measures, although they are limited at this time, could target high-risk patients predicted to have the highest risk of readmission with GI bleeding. Our study has several limitations. The database does not have clinical parameters (eg, specific clinical presentations, medication use, laboratory parameters, type of LVAD) that would further clarify the etiology and severity of GI bleeding events. We could not identify the percentage of patients who required device-assisted (deep) enteroscopy and capsule endoscopy because of the lack of specific ICD procedure codes for these procedures.
Conclusions
Patients with LVAD have a fivefold increased risk of all-cause and GI bleeding readmissions when compared with CHF patients without LVAD. GI bleeding is the third most common reason for readmission after LVAD implantation. Gastroduodenal and small intestinal AVMs are the most common source of bleeding in patients with LVAD. Healthcare costs and resource utilization are higher in LVAD patients with GI bleeding compared with controls, both during index admission and readmissions. Older age and GI bleeding during index admission are independent risk factors for GI bleeding readmission. Chronic anemia is a risk factor for de novo bleeding in these patients. SBE seems like a reasonable first-line study to evaluate the upper GI tract and maximize the therapy of AVMs. Further studies should evaluate the benefit of risk modification to the risk of GI bleeding and other outcomes in patients with LVADs. In addition, studies should evaluate the role of early small bowel evaluation (enteroscopy, capsule endoscopy, or both) in the evaluation and treatment of GI bleeding in these patients. 
